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Letter to the Editor
analogue scale (range: “not at all” to “very”); Patient 0 answered 
the same item on a 7-point scale.
Five participants tapered their medication without an increase 
in depressive symptoms. Patients 0 and 1 reported an increase in 
depressive symptoms. A nonparametric change point analysis (ecp 
R package; [8]) of the weekly assessed depression subscale of the 
Symptom Checklist-90 showed a significant (p < 0.005) increase in 
depressive symptoms, which coincided with the timing of the self-
reported increase. It is unlikely that this reflects withdrawal effects, 
since (a) Patients 0 and 1 did not report physical withdrawal effects 
that impaired functioning in any way, and (b) depressive symp-
toms did not significantly increase until weeks after tapering was 
completed, which would be an unlikely timing for withdrawal 
symptoms [9]. Late-onset withdrawal disorders cannot be ruled 
out.
We used exponentially weighted moving average (EWMA) 
charts to detect structural changes in restlessness prospective- 
ly [10]. After each measurement of restlessness (Yt), a running 
 estimate of the mean level of restlessness was updated using 
 EWMAt = λ × Yt + (1 – λ) × EWMAt–1. The EWMA is a weighted 
average over available observations; the more recent an observa-
tion, the higher the associated weight. Parameter λ controls the 
rate at which the weights decrease. To detect a potentially small 
increase in the mean, a low λ was used (λ = 0.05). An even lower 
λ = 0.01 was used for Patient 0 to smooth out some of the erratic 
behavior caused by the discrete answering scale. We controlled for 
autocorrelation if AR (1) had a lower AICc than AR (0) to prevent 
false alarms caused by high autocorrelation. To limit the influence 
of extreme values, data points > 3 SDs from the mean of the first 
100 observations were Winsorized. After each questionnaire, the 
updated EWMA was marked as potentially alarming if it exceeded 
a bandwidth calculated based on the first 100 observations (L = 3; 
see [10] for technical details).
Results are presented in Figure 1. The EWMA charts demon-
strate an alarming rise in restlessness more than 2 months before 
the increase in depressive symptoms of Patients 0 and 1. No false 
alarms were found in the other patients.
Post hoc analyses showed that total negative affect and posi-
tive affect scores did not have the same capacity to signal future 
increase in depressive symptoms. EWMA charts showed (a) de-
creasing negative affect and increasing positive affect scores in 
Patient 0 before the increase in depressive symptoms, and (b) 
false alarms in 3 out of the 5 patients who did not show any in-
crease in depressive symptoms (full results available upon re-
quest).
This study indicates that monitoring restlessness could be a 
valuable method in clinical practice for the early detection of im-
pending increase in depressive symptoms because (a) it can pro-
vide risk assessment for individual patients rather than at a group 
level; (b) it can continuously update the risk assessment in real time 
while data is collected; and (c) the statistical implementation and 
Dear Editor,
Many patients are treated for their depressive symptoms with 
antidepressants. After discontinuation of all classes of antidepres-
sants, the risk of depressive symptoms is higher than in patients 
who continue treatment [1–3]. However, tapering of antidepres-
sants remains common in clinical practice because (a) many pa-
tients experience unwanted side effects; (b) prolonged use of anti-
depressants may worsen the long-term course of the depression [4, 
5]; and (c) a substantial proportion of patients is able to taper with-
out an increase in depressive symptoms [1–3]. Real-time monitor-
ing of the risk of depressive symptoms during the tapering of med-
ication may be useful. If the risk is increasing, tapering could be 
put on hold until the risk decreases, or stopped if the risk remains 
elevated.
A symptom that may be valuable for monitoring the risk of de-
pressive symptoms is restlessness. The participant of the first study 
demonstrating early signs of an upcoming increase in depressive 
symptoms [6] (hereafter Patient 0) spontaneously mentioned that 
he noticed an increase in restlessness starting before the onset of 
core depressive symptoms (personal communication). Restless-
ness is also a defining symptom in generalized anxiety, the most 
frequently described symptom in prodromal phases of depression 
[7]. The aim of the current paper is to assess if a rise in ecological 
momentary assessments of restlessness during or after tapering of 
antidepressants can be found before an increase in depressive 
symptoms, but not in patients who tapered without such an in-
crease.
The participants were 6 individuals with a history of depression 
who made a shared decision with their medical doctor to taper 
their antidepressants. These patients (1–6) filled in a maximum of 
3 daily questionnaires using a 5.5-h fixed interval experience sam-
pling protocol for 95–183 days during and after open-label taper-
ing of their antidepressant (for the type of medication and tapering 
schedule, see Fig. 1). Patient 0, whose data were already collected, 
was added to this sample. Patient 0 collected up to 10 daily ques-
tionnaires before, during, and after gradual tapering (for details, 
see [6]). Patients 1–6 answered the item “I feel restless” on a visual 
Received: April 26, 2018
Accepted after revision: April 24, 2019
Published online: June 28, 2019
© 2019 The Author(s)
Published by S. Karger AG, Basel
www.karger.com/pps
Psychother Psychosom
Increasing Restlessness Signals Impending 
Increase in Depressive Symptoms More than 2 
Months before It Happens in Individual Patients
Arnout C. Smit    Evelien Snippe    Marieke Wichers    
ICPE, Department of Psychiatry, University Medical Center 
Groningen, University of Groningen, Groningen, The Netherlands
Arnout C. Smit
ICPE, Department of Psychiatry
University Medical Center Groningen, University of Groningen
Hanzeplein 1, NL–9713 GZ Groningen (The Netherlands)
E-Mail a.c.smit @ umcg.nl
DOI: 10.1159/000500594
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
Smit/Snippe/WichersPsychother Psychosom2
DOI: 10.1159/000500594
interpretation are relatively straightforward. This allows clinicians 
and patients to reevaluate the tapering schedule every time a new 
questionnaire is filled in.
Considering the consistent results, it seems unlikely that the 
findings are caused by chance alone, despite the small sample size. 
However, replication is warranted, and future studies with a larger 
sample are needed to assess to whom these results generalize. Spe-
cifically, it should be studied if restlessness also signals an upcom-
ing increase in depressive symptoms in individuals who tapered 
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Fig. 1. EWMA charts of self-reported restlessness over time in pa-
tients tapering their antidepressants. Black dots represent the 
EWMA of restlessness scores (scales are indicated on the left verti-
cal axes). Dots are colored grey if the EWMA was higher than 
would have been expected given the process has not changed com-
pared to the first 100 observations. The dashed line represents the 
dosage of the tapered antidepressant when known (scales and an-
tidepressant names are indicated on the right vertical axes). Charts 
of Patients 3 and 6 were controlled for autocorrelation; for the 
other patients, the regular EWMA charts are reported.




Current data provide no insight in why restlessness increased 
in Patients 0 and 1. As hypothesized, restlessness may have in-
creased as prodrome of depression. An alternative explanation is 
that the increase in restlessness was a withdrawal effect of the 
medication, suggesting that Patients 0 and 1 may have been more 
vulnerable to experience an increase in depressive symptoms be-
cause of withdrawal effects. Though more research in this area is 
needed, the ability to forecast a future increase in depressive 
symptoms is promising for clinical applications regardless of the 
mechanism.
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